In CRC, KRAS mutations have decreased ROS production and enhanced mitochondrial OXPHOS efficiency by activating mitochondrial phospholipid synthesis via the upregulation of transcriptional factors HIF-1α and HIF-2α (Chun et al., 2010). The gene discussed is KRAS; the disease is colorectal carcinoma.